Olmesartan

Introduction Overview

Generic Name

olmesartan

Brand Name

Benicar

Dosage Form

oral tablet (5 mg; 20 mg; 40 mg)

Drug Class

Angiotensin receptor blockers

Pharmacokinetics

Absorption:
Olmesartan medoxomil is a prodrug that is rapidly absorbed and hydrolyzed by esterases in the gastrointestinal tract to its active form, olmesartan. Following oral administration, peak plasma concentrations are reached in approximately 1 to 2 hours. The absolute bioavailability is approximately 26%, which reflects the extent of absorption and first-pass metabolism. Food intake does not significantly affect the bioavailability of olmesartan, allowing flexible administration with or without meals.

Distribution:
Olmesartan exhibits a volume of distribution of approximately 16 to 29 liters, indicating moderate distribution into body tissues. It is highly bound to plasma proteins (~99%), primarily albumin, which influences its pharmacokinetic profile and interaction potential. The drug has minimal penetration across the blood-brain barrier, consistent with its antihypertensive action primarily mediated through systemic vasculature.

Metabolism:
Olmesartan undergoes minimal hepatic metabolism; it is not significantly metabolized by cytochrome P450 enzymes, reducing the potential for many drug-drug interactions. The absence of significant metabolism also accounts for its predictable pharmacokinetics across different patient populations. This metabolic stability allows for administration without extensive concern for hepatic impairment adjusting dose, although clinical judgment is advised.

Elimination:
The elimination half-life of olmesartan is approximately 13 hours, supporting once-daily dosing. It is primarily eliminated unchanged via the feces (about 60%), with approximately 35% excreted renally. Due to this dual excretion, patients with renal impairment may require monitoring but generally do not require dose adjustment unless severe. Olmesartan’s clearance is not significantly altered by age or gender, and steady-state plasma concentrations are achieved within 5 to 7 days of consistent dosing.

Dosage Forms

Available Dosage Forms:
Olmesartan is available as oral tablets in the following strengths: 5 mg, 20 mg, and 40 mg. These tablets are designed for once-daily administration and are suitable for both adult and pediatric patients.

Dosages for Adults and Adolescents:
For adult patients with hypertension, the initial dose is generally 20 mg orally once daily. If adequate blood pressure control is not achieved after two weeks, the dose may be increased to a maximum of 40 mg once daily. The maximum recommended dose is 40 mg daily. For patients at risk of intravascular volume depletion, such as those on diuretics or with impaired renal function, initiation requires careful supervision and consideration of starting at a lower dose.

Specific Patient Populations:
In pediatric patients aged 6 to 16 years, dosing is weight-based. Children weighing 20 to less than 35 kg receive an initial dose of 10 mg once daily, which may be increased to 20 mg if needed after two weeks. Children weighing 35 kg or more start at 20 mg once daily, with a possible increase to 40 mg daily. For children unable to swallow tablets, an extemporaneous suspension can be prepared by a pharmacist to ensure accurate dosing. Dose adjustments may be necessary based on clinical response and tolerability.

Clinical Guidelines:
Olmesartan should be administered once daily with or without food. Tablet storage requires a room temperature environment away from moisture and heat. When using liquid formulations made from tablet suspensions, refrigeration is advised, and any unused liquid should be discarded after four weeks. Patient adherence to therapy is critical, given the delayed onset of antihypertensive effects up to two weeks, and lifelong treatment may be warranted to maintain blood pressure control.

Mechanism Of Action

Olmesartan is a potent and selective angiotensin II type 1 (AT1) receptor antagonist. It competitively inhibits the binding of angiotensin II to the AT1 receptor located on vascular smooth muscle and adrenal gland cells. By blocking angiotensin II-mediated vasoconstriction, aldosterone secretion, and sympathetic activation, olmesartan effectively reduces systemic vascular resistance and lowers arterial blood pressure.

At the molecular level, olmesartan binds with high affinity to the AT1 receptor, preventing angiotensin II from exerting its vasopressor and aldosterone-secreting effects. This inhibition leads to vasodilation, decreased peripheral resistance, diminished aldosterone release resulting in reduced sodium and water retention, and attenuation of cardiac and vascular remodeling processes which are characteristic of chronic hypertension.

Cellular pathways targeted by olmesartan involve inhibition of G-protein coupled receptor signaling cascades triggered by angiotensin II. This results in decreased intracellular calcium mobilization in vascular smooth muscle cells and reduced activation of pro-fibrotic and pro-inflammatory pathways, contributing to cardiovascular and renal protection.

Clinically, olmesartan offers sustained blood pressure reduction without the cough commonly associated with ACE inhibitors, making it a valuable therapeutic agent particularly in patients intolerant to ACE inhibitors. Its mechanism also supports benefits in delaying progression of renal disease in hypertension. Comparative studies have shown that olmesartan has equivalent or superior antihypertensive efficacy compared to other ARBs such as losartan and valsartan, with a favorable safety profile. Ongoing research continues to elucidate its pleiotropic effects beyond blood pressure control, including possible benefits in endothelial function and anti-inflammatory activity.

Pharmacological Actions

Selective antagonist of angiotensin II type 1 (AT1) receptors.
Inhibits vasoconstriction mediated by angiotensin II resulting in vasodilation.
Reduces aldosterone secretion leading to decreased sodium and water retention.
Lowers systemic vascular resistance and blood pressure.
Provides renoprotective effects by reducing glomerular hypertension.
Attenuates cardiac remodeling and hypertrophy associated with hypertension.
Does not inhibit bradykinin degradation, minimizing risk of cough.
Exhibits anti-inflammatory properties within vascular tissues.
Promotes improved endothelial function by blocking angiotensin II effects.
Supports reduction in oxidative stress in cardiovascular system.
Demonstrates long half-life, enabling once-daily dosing for consistent effects.
Minimal metabolism by cytochrome P450 enzymes, reducing drug interaction potential.
Effective in both adult and pediatric populations for hypertension management.

Therapeutic Or Clinical Uses

Treatment of essential hypertension in adults.
Management of high blood pressure in pediatric patients aged 6 years and older.
Used as monotherapy or in combination with other antihypertensives for blood pressure control.
Reduction of cardiovascular morbidity associated with hypertension.
Potential use in protecting renal function in hypertensive patients.
Adjunct therapy in patients intolerant to ACE inhibitors.
Treatment regimens requiring once-daily dosing to improve patient adherence.
Management of hypertension in patients with coexisting comorbidities such as diabetes (with caution).
Part of therapeutic protocols aiming at lowering risk of stroke and myocardial infarction.
Option for patients requiring ARB therapy with minimal metabolic drug interactions.
Use in patients on low sodium diets or with volume depletion under supervision.
Off-label considerations include migraine prophylaxis and heart failure adjunct therapy, under clinical discretion.
Useful in patients at risk for renal impairment due to hypertensive nephropathy when monitored.

Side Or Adverse Effects

Commonly reported dizziness, especially during initiation of therapy.
Hypotension and related symptoms such as light-headedness or syncope in volume-depleted patients.
Hyperkalemia manifested as nausea, muscle weakness, tingling sensations, or arrhythmias.
Gastrointestinal disturbances including diarrhea in some cases.
Allergic reactions such as rash, urticaria, angioedema potentially serious.
Rare instances of acute kidney injury particularly in patients with renal artery stenosis.
Fatigue or asthenia reported during treatment.
Occasional headache and upper respiratory tract infections.
Potential for severe diarrhea and weight loss indicative of olmesartan-associated enteropathy.
Abdominal pain or discomfort as noted in post-marketing surveillance.
Elevated serum creatinine or blood urea nitrogen in sensitive patients.
Electrolyte imbalances including sodium depletion.
Very rare reports of hepatic enzyme elevation.
Orthostatic hypotension especially in elderly or concurrent diuretic users.
Possible cough, although significantly less frequent than with ACE inhibitors.

Precautions

Do not use in patients with known allergy or hypersensitivity to olmesartan.
Use cautiously in patients with intravascular volume depletion or on concomitant diuretic therapy to avoid symptomatic hypotension.
Monitor renal function periodically especially in patients with renal impairment or congestive heart failure.
Avoid potassium supplements or potassium-containing salt substitutes unless explicitly recommended by a healthcare provider.
Exercise caution in patients with bilateral renal artery stenosis due to risk of impaired renal function.
Consider alternative therapy during pregnancy due to risk of fetal harm; discontinue if pregnancy occurs.
Use caution when administering with NSAIDs, lithium, or other antihypertensive agents for potential interactions.
Adjust dosage in pediatric populations based on weight and clinical response under medical supervision.
Advise patients regarding potential dizziness and counsel on slow positional changes to prevent falls.
Avoid use with aliskiren-containing medications in patients with diabetes or renal impairment.
Evaluate for possible olmesartan-induced enteropathy if patients develop unexplained severe diarrhea and weight loss.
Advise against breastfeeding while using olmesartan due to insufficient safety data.
Consider electrolyte monitoring during concurrent use of medications affecting potassium levels.
Educate patients on adherence despite asymptomatic nature of hypertension to prevent complications.
Discontinue promptly and seek emergency help if signs of angioedema or severe hypersensitivity occur.

Warnings

Do not use olmesartan during pregnancy; it can cause fetal injury or death, especially in the second and third trimesters.
Discontinue therapy immediately if pregnancy is detected and consult for alternative antihypertensive therapy.
Risk of hyperkalemia when used with potassium supplements, potassium-sparing diuretics, or other agents increasing potassium.
Risk of symptomatic hypotension and acute renal impairment in volume-depleted patients or those with bilateral renal artery stenosis.
Use with aliskiren-containing products is contraindicated in diabetic patients due to risk of adverse renal effects.
Potential for severe sprue-like enteropathy characterized by chronic diarrhea and substantial weight loss.
Risk of angioedema, particularly in patients with a history of angioedema from other renin-angiotensin system inhibitors.
Caution advised in elderly patients who may be more sensitive to blood pressure lowering effects and dehydration.
NSAIDs may reduce antihypertensive efficacy and increase risk of renal impairment when combined with olmesartan.
Use caution in patients with hepatic impairment although metabolism is minimal; no dosage adjustment generally required.
Avoid abrupt withdrawal to prevent exacerbation of hypertension.
Monitor blood pressure regularly to avoid excessive hypotension.
In patients with salt depletion or hyponatremia, initiation may precipitate severe hypotension.
Patients should be warned about the possibility of dizziness and advised to avoid driving or operating heavy machinery until effects are known.
Store oral suspensions properly as per recommendations to maintain efficacy and safety.

Contraindication

Known hypersensitivity to olmesartan or any component of the formulation.
Pregnancy due to teratogenic effects and potential fetal harm.
Concomitant use with aliskiren-containing products in patients with diabetes mellitus.
History of angioedema associated with previous treatment with angiotensin receptor blockers or ACE inhibitors.
Severe hypersensitivity reactions previously recorded with olmesartan use.
Use in patients with bilateral renal artery stenosis without careful medical supervision.
Use in breastfeeding mothers due to lack of data on safety and potential risk to the infant.
Concomitant use with potassium-sparing diuretics or potassium supplements unless medically supervised.
Severe hepatic impairment although no direct contraindication, liver dysfunction requires cautious use.
Patients with severe hypotension or volume depletion without correction prior to administration.

Drug Interactions

Concurrent use with potassium supplements or potassium-sparing diuretics increases risk of hyperkalemia.
NSAIDs (e.g., ibuprofen, naproxen, celecoxib) may reduce antihypertensive effect and increase risk of renal impairment.
Lithium clearance may be reduced; monitor lithium levels and toxicity signs.
Diuretics, when combined, may enhance hypotensive effects but also increase risk for volume depletion.
Aliskiren-containing medications contraindicated in diabetics due to increased risk of renal impairment.
Colesevelam can interfere with olmesartan absorption; separate dosing by at least 4 hours.
Other antihypertensive agents may have additive effects increasing risk of hypotension.
Drugs affecting the renin-angiotensin-aldosterone system may potentiate hyperkalemia risk.
Concomitant use with NSAIDs and diuretics may cause acute renal failure in susceptible individuals.
Combination with other ARBs or ACE inhibitors is generally not recommended due to increased adverse effect risk.
Potential drug interactions with nephrotoxic agents require careful monitoring.
Corticosteroids may antagonize the antihypertensive effects of olmesartan.
Non-prescription herbal supplements like St. John's Wort have potential unknown interactions and should be used cautiously.
Drugs altering hepatic blood flow or gastrointestinal motility may alter olmesartan pharmacokinetics.
Co-administration with hypoglycemic agents does not have significant interaction but blood glucose should be monitored.

Preparations Of The Drug

Oral tablets: 5 mg strength for low-dose initiation or pediatric use.
Oral tablets: 20 mg standard dose formulation for adult and pediatric patients.
Oral tablets: 40 mg for maximum dosage strength in adults and adolescents.
Extemporaneous liquid suspension prepared by pharmacists for pediatric patients who cannot swallow tablets.
Commercial tablet packaging designed for storage at controlled room temperature, protected from moisture and heat.
Liquid suspension recommended to be stored refrigerated and discarded after 4 weeks to maintain efficacy.
Tablets are film-coated for ease of swallowing and stability.
Tablet formulations do not contain significant allergens, suitable for most patients with sensitivities.
Packaging designed to maintain medication integrity during transport and storage.
Used in conjunction with dosing devices (measuring syringes) when administered as suspension for pediatric cases.